Share this article
Share this article
Celebrated neurologist, psychiatrist and plant-medicine expert Dr. Dan Engle brings years of understanding of psychedelic medicine into research with Mind Cure.
VANCOUVER, BC, Feb. 17, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( Mind Cure or the Company ) is pleased to announce the engagement of Dr. Dan Engle as Mind Cure s Primary Investigator Consultant. Dr. Engle is Board Certified in Psychiatry and Neurology, with a clinical practice that combines functional medicine, integrative psychiatry, neuro-cognitive restoration. He is celebrated for contribution to understanding of traumatic brain injury and concussion recovery with his book
Financial News Media | Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing
financialnewsmedia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialnewsmedia.com Daily Mail and Mail on Sunday newspapers.
Envisioning a psychedelic future for Philadelphia s USciences as it pairs with Compass Pathways for a Drug Discovery Center
inquirer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from inquirer.com Daily Mail and Mail on Sunday newspapers.
MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index
News provided by
Share this article
Share this article
Mind Cure among respected life science and therapeutic technology peers in first ever Psychedelic ETF & North American Psychedelic Index
VANCOUVER, BC, Jan. 21, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ) is pleased to announce its inclusion among 17 psychedelic companies in the first ever Psychedelic ETF. Horizon s Psychedelic ETF, is expected to commence trading Jan. 26, 2021 under ticker PSYK on the NEO exchange.
The ETF includes companies in the Canadian legal psychedelics industry, as well as U.S. companies engaged in legal activities involving psychedelic drugs and substances. The purpose of the ETF is to invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances.